arrow
D

Dorff, Sarah E.

us food & drug administration (fda)
H指数:0
被引数:37

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2024-06-140
PRE
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
2023-05-2318
PRE
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
2022-06-2163
OA
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
2020-11-0989
PREAI
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

FDA批准摘要: Ivosidenib用于异柠檬酸脱氢酶-1突变的复发或难治性急性髓系白血病

2019-06-03113
OAAI
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs
2016-09-1559
OAAI